ChemoMetec growth outlook raised on instrument sales
ChemoMetec reported revenue rising 3% to DKK 511 million, EBITDA margin at 55%, with life science making up 95% of revenue and next-year revenue growth guidance of 7–13%.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.